<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720313</url>
  </required_header>
  <id_info>
    <org_study_id>MOH_2020-12-22_009584</org_study_id>
    <nct_id>NCT04720313</nct_id>
  </id_info>
  <brief_title>HB10101 Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Dose Escalation and Safety Study of HBI0101 CART in BCMA-Expressing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple&#xD;
      Myeloma Patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intention with HBI0101 CART is to follow the chimeric antigen receptor T-cells (CART)&#xD;
      approach, as for approved products, but target the B cell maturation antigen (BCMA) rather&#xD;
      than the CD19 antigen targeted by KYMRIAHTM (tisagenlecleucel) and YESCARTATM (axicabtagene&#xD;
      ciloleucel).&#xD;
&#xD;
      Importantly, successful results from at least three clinical trials of a BCMA targeted CAR T&#xD;
      therapy were published (Zhao 2018, Brundo 2018, Raje 2019), with excellent results obtained&#xD;
      for relapsed or refractory multiple myeloma (MM) patients, that validate the approach. The&#xD;
      CAR vector employed for HBI0101 CART is almost identical to the vector employed for the&#xD;
      clinical study reported by Raje 2019, therefore, a strong therapeutic response is expected&#xD;
      also for HBI0101 CART together with a similar manageable safety profile&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multiple Myeloma Patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of MTD</measure>
    <time_frame>21 days</time_frame>
    <description>Part A: Determination of MTD Part B: Confirmation of selected dose tested (at or below MTD) ( safety )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>according to the IMWG Uniform Response Criteria for Multiple Myeloma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>according to the IMWG Uniform Response Criteria for Multiple Myeloma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Dose Escalation and Safety</condition>
  <arm_group>
    <arm_group_label>CART BCMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose escalation phase (Part A) will include the following doses of CAR-positive (CAR+) T cells: 150×10^6, 450×10^6, 800×10^6 or 1200 ×10^6 The expansion phase (Part B) will include a dose between 450×10^6 to 800×10^6 CAR-positive (CAR+) T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CART BCMA</intervention_name>
    <description>HBI0101 CART is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA. The HBI0101 CART is provided fresh without cryopreservation.</description>
    <arm_group_label>CART BCMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
               -  Voluntarily signed informed consent form (ICF)&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2&#xD;
&#xD;
               -  Diagnosis of MM with relapsed or refractory disease and have had at least 3&#xD;
                  different prior lines of therapy including proteasome inhibitor, immunomodulatory&#xD;
                  therapy and at least one antibody therapy.&#xD;
&#xD;
               -  Subjects must have measurable disease, including at least one of the criteria&#xD;
                  below:&#xD;
&#xD;
                    -  Serum M-protein greater or equal to 0.5 g/dL&#xD;
&#xD;
                    -  Urine M-protein greater or equal to 200 mg/24 h&#xD;
&#xD;
                    -  Serum free light chain (FLC) assay: involved FLC level greater or equal to 5&#xD;
                       mg/dL (50 mg/L) provided serum FLC ratio is abnormal&#xD;
&#xD;
                    -  A biopsy-proven evaluable plasmacytoma&#xD;
&#xD;
                    -  Bone marrow plasma cells &gt; 20% of total bone marrow cells&#xD;
&#xD;
                    -  Non secretory patient will be allowed provided they have measurable disease&#xD;
                       by PET-CT or bone marrow aspiration, as designated.&#xD;
&#xD;
               -  Women of child-bearing potential (WCBP), must have a negative serum pregnancy&#xD;
                  test prior to treatment. All sexually active WCBP and all sexually active male&#xD;
                  subjects must agree to use effective methods of birth control throughout the&#xD;
                  study&#xD;
&#xD;
               -  Recovery to ≤Grade 2 or baseline of any non-hematologic toxicities due to prior&#xD;
                  treatments, excluding alopecia and Grade 3 neuropathy&#xD;
&#xD;
               -  Ability and willingness to adhere to the study visit schedule and all protocol&#xD;
                  requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Polina Stepensky, prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah university hospital of Jerusalem</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Polina Stepensky, Prof</last_name>
    <phone>972-26777803</phone>
    <email>polina@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liliane DRAY, NSC</last_name>
    <phone>97226777260</phone>
    <email>lilane@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polina Stepensky, Prof</last_name>
      <phone>972-26777803</phone>
      <email>polina@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>liliane Dray, NSC</last_name>
      <phone>972-26777260</phone>
      <email>lilane@hadassah.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Polina Stepensky</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There will be no IPD sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

